Novelty Nobility
June 16, 2025
Company Presentation
Immunology
153A
Novelty Nobility is a clinical stage biotechnology company developing fit-for-purpose antibodies to deliver meaningful therapeutic benefits to patients. Starting with the end in mind, the Company is crafting tailored solutions by matching the right antibody modality to the underlying mechanisms of a specific disease. While this ‘good’ antibody approach can be used in many treatments, this versatility isn’t automatic—it is supported by our design-driven antibody discovery platform, PREXISE®-D, to ensure the best results for each application.
Novelty Nobility is headquartered in Pangyo, South Korea with U.S. offices in Cambridge, MA. For more information, please visit www.noveltynobility.com
Company HQ City:
Seongnam-si
Company HQ State:
Gyeonggi-do
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
NN2802 - an anti-c-Kit antibody for chronic urticaria and other mast cell driven diseases
CEO
Sang-gyu Park
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
5
When you expect your next catalyst update?
clinical updates for NN3201, a c-Kit directed ADC for treating c-Kit expressing cancers
What is your next catalyst (value inflection) update?
June 2026
Website
www.noveltynobility.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}